Printed From BioPortfolio.com
Novartis to bolster oncology portfolio with $3.9 billion acquisition
06:42 EDT 30 Oct 2017 | Pharmafile
Novartis has announced its intention to acquire France’s Advanced Accelerator Applications (AAA) for $3.9 billion in a move to reinforce its oncology portfolio. The deal translates to $41 per share, with the Swiss firm planning to finance the deal with debt.
AAA is a radiopharmaceutical company that develops, manufactures and markets molecular nuclear medicines, a class of therapy which utilises radioisotopes to both diagnose and treat cancer.
Original Article: Novartis to bolster oncology portfolio with $3.9 billion acquisition
